Seattle Genetics highlights Ab-drug conjugate programs

3 November 2008

Washington, USA-based Seattle Genetics has announced data highlighting preclinical findings on two of its antibody-drug conjugate programs, SGN-35 and SGN-19A, as well as research advances with its proprietary ADC technology. The data were being presented at the European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research International Conference on Molecular Targets and Cancer Therapeutics being held in Geneva, Switzerland.

"Our ADC technology is gaining substantial momentum, demonstrated by the four empowered antibodies now in clinical trials between us and our collaborators, as well as progress with multiple preclinical programs," said Clay Siegall, chief executive of the firm. "Data presented on SGN-19A, our anti-CD19 ADC, suggest it may represent a promising addition to the treatment options for non-Hodgkin's lymphoma and other hematologic malignancies, including acute lymphoblastic leukemia. In addition, preclinical research with SGN-35 demonstrates its utility in a variety of Hodgkin's lymphoma settings, including in combination with upfront and salvage chemotherapy regimens, complementing our clinical data on its ability to induce objective responses as a single agent," he added.

Data summary

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight